721 related articles for article (PubMed ID: 32579769)
1. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.
Baba Y; Nomoto D; Okadome K; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H
Cancer Sci; 2020 Sep; 111(9):3132-3141. PubMed ID: 32579769
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
4. Firing Up Cold Tumors.
Cheng WC; Ho PC
Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
[TBL] [Abstract][Full Text] [Related]
6. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Shien K; Papadimitrakopoulou VA; Wistuba II
Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
[TBL] [Abstract][Full Text] [Related]
8. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020
[TBL] [Abstract][Full Text] [Related]
9. Characterization of CD103
Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
11. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma.
Hatogai K; Fujii S; Kitano S; Kojima T; Daiko H; Yoshino T; Ohtsu A; Takiguchi Y; Doi T; Ochiai A
Br J Cancer; 2020 Feb; 122(3):413-420. PubMed ID: 31761900
[TBL] [Abstract][Full Text] [Related]
13. Immunological Responses Associated With Neoadjuvant Therapy in the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma.
Takehara Y; Tamaki T; Mimura K; Saito K; Neupane P; Tada T; Watanabe Y; Hayase S; Saze Z; Yoshimoto Y; Sato H; Kono K; Suzuki Y
Anticancer Res; 2023 Oct; 43(10):4691-4700. PubMed ID: 37772585
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
Okadome K; Baba Y; Yasuda-Yoshihara N; Nomoto D; Yagi T; Toihata T; Ogawa K; Sawayama H; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
Cancer Sci; 2022 Feb; 113(2):399-410. PubMed ID: 34773342
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y
Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.
Chen K; Zhu Z; Zhang N; Cheng G; Zhang F; Jin J; Wu J; Ying L; Mao W; Su D
Med Sci Monit; 2017 Sep; 23():4619-4632. PubMed ID: 28949934
[TBL] [Abstract][Full Text] [Related]
19. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Lee J; Kim B; Jung HA; La Choi Y; Sun JM
Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]